References
- Pincus T, Yazici Y, Sokka T, Aletaha D, Smalen JS. Methotrexate as the “anchor drug” for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol. 2003;21:S179–85.
- Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis. Arthritis Rheum. 2004;50:1740–51.
- Hoshida Y, Xu JX, Fujita S, Nakamichi I, Ikeda J, Tomita Y, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol. 2007;34(2):322–31.
- Kikuchi K, Miyazaki Y, Tanaka A, Shigematu H, Kojima M, Sakashita H, et al. Methotrexate-related Epstein–Barr Virus (EBV)-associated lymphoproliferative disorder–so-called “Hodgkin-like lesion”–of the oral cavity in a patient with rheumatoid arthritis. Head Neck Pathol. 2010;4(4):305–11.
- Dorfman HD, Siegel HD, Perry MC, Oxenhendler R. Non-Hodgkin’s lymphoma of the synovium simulating rheumatoid arthritis. Arthritis Rheum. 1987;30:155–61.
- Dresner E. The bone and joint lesions in acute leukemia and their response to folic acid antagonists. Quart J Med. 1950;19:339.
- Emkey RD, Ragsdale BD, Ropes MW, Miller W. A case of lymphoproliferative disease presenting as juvenile rheumatoid arthritis. Am J Med. 1973;54:825–8.
- Fransen J, Stucki G, van Riel PLCM. Rheumatoid arthritis measures. Disease Activity Score (DAS), Disease Activity Score-28 (DAS-28), rapid Assessment of Disease Activity in Rheumatology (RADAR), and Rheumatoid Arthritis Disease Activity Index (RADAI). Arthritis Rheum. 2003;49:S214–24.
- Hellgren K, Iliadou A, Rosenquist R, Feltelius N, Backlin C, Enblad G, et al. Rheumatoid arthritis, treatment with cortocosteroids and risk of malignant lympomas: results from a case-control study. Ann Rheuma Dis. 2010;69:654–9.
- Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 2007;56(5):1433–9.
- Jawa A, Lieberman AE, Alexieva CCN, Jupiter JB. Primary intra-articular non-Hodgkin’s lymphoma of the elbow. A case report. J Bone Joint Surg Br. 2006;12(88-A):2730–4.
- Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer. 2000;88:497–502.
- Silman AJ, Petrie J, Hazeleman B, Evans SJ. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20-year-follow-up study. Ann Rheum Dis. 1988;47:988–92.
- Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509.
- Harris NL, Swerdlow SH. Methotrexate-associated lymphoproliferative disorders. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and genetics, tumours of haematopoietic and lymphoid tissues, World Health Organization classification of tumours. Lyon: IARC Press; 2001:270–1.
- Ogose A. (in Japanese) (Case report) Cytodiagnosis of knee joint fluid due to the malignant lymphoma. Orthopedics. 2005;56(5):580–1.
- Tokuhira M1, Watanabe R, Nemoto T, Sagawa M, Tomikawa T, Tamaru J, et al. Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis. Leuk Lymphoma. 2012;53(4):616–23.
- Niitsu N, Okamoto M, Nakamine H, Hirano M. Clinicopathologic correlations of diffuse large B-cell lymphoma in rheumatoid arthritis patients treated with methotrexate. Cancer Sci. 2010;101(5):1309–13.